乳腺癌辅助质子与光子放疗患者急性皮肤毒性量化:单机构经验
单机构分析86例乳腺癌术后辅助放疗患者,质子组39例、光子组47例,质子组≥2级放射性皮炎发生率为69.2%,光子组为29.8%(P=0.002);3级放射性皮炎分别为5.1%与4.3%(P=0.848),皮肤色素沉着两组无显著差异,两组均无4-5级毒性。
要点
- 质子组≥2级放射性皮炎发生率为69.2%,光子组为29.8%(P=0.002)。
- 质子组3级放射性皮炎为5.1%,光子组为4.3%(P=0.848),两组均无4-5级毒性。
- 两种放疗方式间皮肤色素沉着发生率无显著差异。
核心结论
- 与光子放疗相比,质子放疗患者≥2级放射性皮炎发生率显著更高,两组3级毒性发生率均很低。
- 两种放疗方式间皮肤色素沉着发生率无显著差异。
- 作者认为应告知女性患者出现2级毒性增加的可能性,尽管这在乳房切除术后或就诊时皮肤受累的情况下可能为医生带来剂量学优势。
研究设计与样本
- 单机构分析86例乳腺癌术后接受辅助放疗(乳房切除术后或肿块切除/保乳术后,伴或不伴区域淋巴结照射)患者的急性放射性皮炎和皮肤色素沉着最高分级。
- 质子笔束扫描组39例,光子放疗组47例。
- 对47例光子患者中的34例和39例质子患者中的33例,在治疗计划系统中回顾性勾画「皮肤」轮廓并计算多个剂量学参数以量化皮肤受照剂量。
主要发现
- χ2分析显示,质子组报告的最高放射性皮炎分级显著高于光子组;≥2级放射性皮炎在质子组和光子组分别为69.2%和29.8%(P=0.002)。
- 3级放射性皮炎在质子组和光子组分别为5.1%和4.3%(P=0.848)。
- 两种放疗方式间皮肤色素沉着发生率总体无显著差异。
- 两组均无4-5级毒性。
临床怎么用
- 作者认为应告知女性患者质子放疗后出现2级毒性增加的可能性。
- 作者认为质子放疗在乳房切除术后设置或就诊时皮肤受累的情况下可能为医生带来剂量学优势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acute skin toxicity in the form of radiation dermatitis (RD) or skin hyperpigmentation (SH) is a common problem experienced by patients undergoing breast irradiation. Proton radiation has been thought to deliver higher doses to skin compared with photon radiation because of differences in the physical properties between photons and protons; however, limited literature exists directly comparing toxicity outcomes. METHODS AND MATERIALS: The highest recorded grades of acute RD and SH were analyzed in 86 patients undergoing adjuvant radiation therapy to the breast with or without regional lymph nodes after lumpectomy (breast-conserving surgery) or mastectomy with either proton pencil-beam scanning (n = 39) or photon (n = 47) radiation therapy within a single institution to analyze differences in severity of acute skin reactions. For 34 of 47 photon and 33 of 39 proton patients, a "skin" contour was retroactively created in our treatment planning systems, and multiple dosimetric parameters were calculated to quantify objective radiation doses received by skin. RESULTS: On χ2 analysis, the highest reported grade of RD was significantly higher in women undergoing proton radiation compared with photon radiation; grade ≥2 RD was present in 69.2% versus 29.8% of patients receiving proton and photon therapy, respectively (P = .002). Rates of grade 3 RD were 5.1% versus 4.3% for proton versus photon radiation, respectively (P = .848). Overall, there were no significant differences in rates of SH between modalities. There were no grade 4 to 5 toxicities in either cohort. CONCLUSIONS: In a comparison with patients receiving photon radiation, a significantly higher rate of grade ≥2 RD was observed in patients undergoing proton radiation, with very low rates of grade 3 toxicity in both groups. Rates of SH did not differ significantly between modalities. Women should be counseled regarding the possibility of increased grade 2 toxicities, although this might present a dosimetric advantage for physicians when treating patients in the postmastectomy setting or when skin was involved on presentation.
引用
- DeCesaris CM, Rice SR, Bentzen SM, et al. Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. Int J Radiat Oncol Biol Phys. 2019. PMID: 31028831. doi:10.1016/j.ijrobp.2019.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。